AZN Astrazeneca PLC

32.67
+0.25  (1%)
Previous Close 32.42
Open 32.74
Price To book 6.06
Market Cap 82720440000
Shares 2,532,000,000
Volume 4,386,930
Short Ratio 3.97
Av. Daily Volume 5,672,584

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released September 7, 2017 - primary endpoint met.
Tezepelumab
Asthma
Expanded approval announced August 28, 2017.
Faslodex (fulvestrant)
Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer
Phase 3 trial commenced 1Q 2017.
Dapa-CKD
Chronic Kidney Disease
Cardiovascular outcome data due 2H 2018.
Dapagliflozin - DECLARE
Type-2 diabetes
Phase 3 data due 2H 2017.
Tralokinumab (STRATOS2)
Severe, uncontrolled asthma
Phase 3 trial commenced 1Q 2017.
Dapa-HF
Heart failure
Phase 3 data due 2H 2018.
Benralizumab - TERRANOVA
COPD
Phase 3 data due 2H 2018.
Farxiga - DECLARE
Cardiovascular Outcomes
Approval announced March 31, 2017.
Tagrisso
Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 data due 2019.
AZD3293
Early Alzheimer's disease
Phase 3 trial did not meet primary endpoint - May 10, 2017.
Tralokinumab (STRATOS1)
Severe, uncontrolled asthma
Phase 3 data due 2018.
Selumetinib - ASTRA
Thyroid cancer
Phase 3 data released July 27, 2017 - PFS improvement noted. Late breaker at ESMO September 9, 2017 showed PFS 18.9 months compared with 10.2 SOC.
Tagrisso - FLAURA
First-line lung cancer
Phase 3 data due 2018.
Roxadustat - ANDES
Anaemia
Phase 3 data due 2018.
PT010
Chronic obstructive pulmonary disease (COPD)
Phase 3 data due 2H 2017.
Moxetumomab
Cancer - leukaemia
Phase 3 data due 1H 2018.
Lynparza
First-line ovarian cancer
Approval announced August 17, 2017.
Lynparza - SOLO 2
Second-line ovarian cancer
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death).
Lynparza
Breast cancer
Phase 3 data released July 27, 2017 - primary endpoint not met. Overall survival data due 1H 2018.
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 data due 2H 2018.
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 data due 1H 2018.
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 data due 2H 2018.
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 data due 1H 2018.
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 data 2H 2017.
Durvalumab +/- tremelimumab (ARCTIC)
Lung cancer
Phase 3 interim analysis released May 12, 2017 - PFS primary endpoint already met. Regulatory filing due 2H 2017. Late breaker at ESMO September 9, 2017 showed PFS 16.8 months v 5.6 months for placebo.
Durvalumab (PACIFIC)
Lung cancer
Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061).
Bydureon
Type 2 Diabetes
Phase 3 data due 1Q 2018.
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3 data due 2H 2018.
Anifrolumab
Lupus
Priority Review announced August 2, 2017. Assume 6-month review rendering a PDUFA date on or around February 1, 2018.
Acalabrutinib
Relapsed or Refractory Mantle Cell Lymphoma
BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.
Urothelial carcinoma - Bladder cancer
Bladder cancer
Second CRL issued March 17, 2017.
ZS-9
Hyperkalaemia
Approval announced February 28, 2017.
Saxagliptin and dapagliflozin
Type-2 diabetes
PDUFA 4Q 2017. Exact data not confirmed. 12/31/2017 used solely for entry into the BioPharmCatalyst database. Actual date will most likely be BEFORE.
Benralizumab
Severe, uncontrolled asthma

Latest News

  1. 3 High-Yield Pharmaceutical Stocks
  2. Oncology Space in Focus this Week on ESMO Presentations
  3. Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile and Fewer CV Events in Patients with Type-2 Diabetes at Wide Range of CV Risk
  4. AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs
  5. [$$] Moderna Therapeutics raises hopes for drug after human trials
  6. Moderna, AstraZeneca heart drug succeeds early-stage trial
  7. Astra's Farxiga results may open up type 1 diabetes opportunity
  8. Bristol-Myers Reports Positive Results from Melanoma Study
  9. AstraZeneca's Asthma Candidate Shows Promising Results
  10. Regeneron: When Good Isn't Good Enough
  11. AstraZeneca's Lung Cancer Study Data Promising, Shares Spike
  12. U.K. stocks edge higher as fears over Irma, North Korea ease
  13. [$$] Teva poaches chief from Danish drugmaker Lundbeck
  14. AstraZeneca Wins in Cancer by Going Its Own Way
  15. [$$] AstraZeneca, Merck and Inctye boosted by cancer treatment advances
  16. AstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results
  17. Cancer immunotherapy proves itself in earlier-stage disease
  18. AstraZeneca rebuilds cancer drug hopes with new lung data
  19. AstraZeneca CEO, worried by Brexit, not signing UK government letter
  20. AstraZeneca shares tick higher on lung cancer drug study results